Access Alto Pharmacy Stock and Financial Details

Alto Pharmacy stock price

Forge Price ¹

Price not available

Last Closed Trade ²

Close Date

xx/xx/xx

Last Closed Trade Price

$xx.xx

Last Funding Round (LFR)

Date

xx/xx/xx

Price per Share

$xx.xx

Access Stock Price

Alto Pharmacy funding rounds and valuation

Funding history chart

Funding round details

	Funding Date	Share Class	Amount Raised	Price per Share	Post-Money Valuation	Key Investors
	09/25/2023	Series FF	$101.74MM	$xx.xx	$799.9MM	What If Ventures
Price per Share $xx.xx Shares Outstanding 16,560,717 Liquidation Pref Order 1 Liquidation Pref As Multiplier 2.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors What If Ventures
	09/25/2023	Series CCC-4	$15.69MM	$xx.xx	$799.9MM	What If Ventures
Price per Share $xx.xx Shares Outstanding 2,525,760 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors What If Ventures
	09/25/2023	Series EEE-1	$2.58MM	$xx.xx	$799.9MM	What If Ventures
Price per Share $xx.xx Shares Outstanding 151,690 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors What If Ventures
	01/27/2022	Series EEE	$200MM	$xx.xx	$1.51B	Softbank
Price per Share $xx.xx Shares Outstanding 12,936,611 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Softbank
	02/04/2020	Series DDD	$246.4MM	$xx.xx	$751.58MM	Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Softbank, Zola Global
Price per Share $xx.xx Shares Outstanding 25,130,023 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Softbank, Zola Global
	06/19/2019	Series CCC	$30MM	$xx.xx	$261.15MM	Undisclosed Investors
Price per Share $xx.xx Shares Outstanding 4,830,751 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Undisclosed Investors
	12/05/2018	Series CCC-1	$41.03MM	$xx.xx	$164.84MM	Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Zola Capital
Price per Share $xx.xx Shares Outstanding 8,616,165 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Zola Capital
	12/05/2018	Series CCC-2	$9.38MM	$xx.xx	$164.84MM	Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Zola Capital
Price per Share $xx.xx Shares Outstanding 2,316,805 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Greenoaks Capital, Jackson Square Ventures, Olive Tree Capital, Zola Capital
	06/12/2017	Series BBB	$17.15MM	$xx.xx	$55.98MM	Craig Sherman, Daniel Kan, Greenoaks Capital, Jackson Square Ventures, Justin Kan, Rahul Mehta
Price per Share $xx.xx Shares Outstanding 5,902,610 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Craig Sherman, Daniel Kan, Greenoaks Capital, Jackson Square Ventures, Justin Kan, Rahul Mehta
	06/10/2016	Series AAA	$5.95MM	$xx.xx	$17.25MM	Undisclosed Investors
Price per Share $xx.xx Shares Outstanding 4,879,912 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Undisclosed Investors
	06/10/2016	Series AAA-1	$649,991.76	$xx.xx	$17.25MM	Undisclosed Investors
Price per Share $xx.xx Shares Outstanding 774,722 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 6.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Undisclosed Investors

Access Stock Price

Alto Pharmacy stock FAQs

To buy and sell Alto Pharmacy stock

Can you buy Alto Pharmacy stock?

You can no longer buy Alto Pharmacy stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

How to buy Alto Pharmacy stock?

Can you sell Alto Pharmacy stock?

You can no longer sell stock of Alto Pharmacy on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.

How to sell Alto Pharmacy stock?

To learn more about Alto Pharmacy stock

Is Alto Pharmacy a public company?

Alto Pharmacy is now a public company.

What is Alto Pharmacy’s stock price?

The stock price of Alto Pharmacy is not currently available.

What is Alto Pharmacy’s stock ticker symbol?

The ticker symbol of Alto Pharmacy is not currently available.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Leadership and board

Leadership

Alicia Davis

Chief Executive Officer

Nihar Bhatt

Chief Financial Officer

Mike McClay

Chief Technology Officer

Board

John Westcott

SoftBank Investment Advisers

Neil Shah

Greenoaks Capital Partners

Nichola Eliovits

Olive Tree Capital

Alto Pharmacy news and media highlights

Blog

Startup Trends: 5 potential “soonicorns”

February 14, 2025

A private company is considered a “Unicorn” when it surpasses one billion dollars in value. In 2024, 56 U.S. companies reached Unicorn status, according to TechCrunch, down from 86 in 2023. Many of these firms are in AI, cybersecurity, and health tech.

drugstorenews 10/19/2023

Mark Cuban Cost Plus Drug Company partners with Alto Pharmacy

Mark Cuban's Cost Plus Drug Company partners with Alto Pharmacy to provide low-cost prescription delivery to Team Cuban Card holders.

WSJ 12/24/2022

This Former Auto Executive Is Now CEO of a Billion-Dollar Online Pharmacy

Alicia Boler Davis was the most senior Black executive in the auto industry before joining Amazon, and later, Alto Pharmacy. Her mentors, she says, have pushed her to continually raise the bar for herself.

Fortune 10/28/2022

A Softbank-backed pharmacy startup is working to tackle a $300-billion-a-year prescription drug crisis

For years, the $500 billion prescription drug industry has loomed as an enticing target for disruption-minded entrepreneurs and corporations alike.

FierceHealthcare 08/17/2022

On track to hit $1B in revenue this year, Alto Pharmacy tapped an Amazon exec to lead its next phase of growth

Jamie Karraker and Mattieu Gamache-Asselin, who both previously worked at Facebook, bought an independent "mom-and-pop" pharmacy in San Francisco's Mission District to learn the workflows and pain points for consumers, doctors and pharmacists.

Explore private companies in the Digital Health sector

Sector: Healthcare

Subsector: Digital Health

					Last Funding Round
Company		Forge Price	Forge Price Change ⁵	Last Closed Trade	Share Class	Post-Money Valuation	Price per Share	Amount Raised
	BetterUp	--	--	$xx.xx	Series E	$4.75B	$xx.xx	$340MM
	Doctolib	--	--	$xx.xx	Series F	--	--	--
	Headspace	--	--	$xx.xx	Series B	$298.33MM	$xx.xx	$38.65MM
	Hinge Health	$31.00	-22.11%	$xx.xx	Series E	$6.2B	$xx.xx	$400MM
	Included Health	--	--	$xx.xx	Series E	$1.13B	$xx.xx	$103.04MM
	KRY	--	--	$xx.xx	--	--	--	--
	OURA	--	--	$xx.xx	--	--	--	--
	Omada Health	--	--	$xx.xx	Series E	$1.02B	$xx.xx	$192MM
	Real	--	--	$xx.xx	--	--	--	--
	ZocDoc	$7.07	-0.56%	$xx.xx	Series D-2	$2.62B	$xx.xx	$100MM

See All Companies

Forge is your trusted partner to buy and sell Alto Pharmacy stock

Forge is the trusted platform for buying and selling private company stock. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

First time buying private market stock?

New to selling your private company stock?

Updated on: Mar 29, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.

Alto Pharmacy stock